approval
saveQULIPTA (ATOGEPANT) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 5
- approvalQULIPTA (ATOGEPANT) — FDA approvalSep 30, 2025 · 370d ago
- approvalQULIPTA (ATOGEPANT) — FDA approvalJun 10, 2025 · 482d ago
- approvalQULIPTA (ATOGEPANT) — FDA approvalMar 21, 2025 · 563d ago
- approvalQULIPTA (ATOGEPANT) — FDA approvalApr 17, 2023 · 1267d ago
- approvalQULIPTA (ATOGEPANT) — FDA approvalSep 28, 2021 · 1833d ago
same company · ±60 days · 6
- approvalatogepant: QULIPTA (ATOGEPANT) — FDA approvalJun 10, 2025
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025
- approvaladalimumab: HUMIRA (ADALIMUMAB) — FDA approvalJul 16, 2025
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
comments(0)
5-min edit window · permanent after that